Dutch antibody company begins anthrax vaccine trial

The Dutch human antibody technology company IQ Therapeutics BV has begun a phase I clinical trial for IQ-DAA, a combination of two monocolonal human antibodies that is directed against the deadly infectious disease anthrax.

IQ-DAA has been developed by the company to treat inhaled anthrax and has been shown to be highly effective in pre-clinical experiments, even in the disease’s advanced stages. Anthrax is caused by the spore-forming bacterium Bacillus anthracis, which has previously been used in mail-based bioterror attacks.

If effective, the treatment would be one of the few options available for anthrax after the initial appearance of symptoms.

“IQ Therapeutics is pleased to initiate this clinical trial,” Dr. Roland Lageveen, chief executive officer of IQ Therapeutics, said. “It will provide valuable information regarding the safety and kinetics of IQ-DAA in humans, including an initial perspective of its potential to reach efficacious levels in human. It illustrates IQ Therapeutics' commitment to and advancements in developing fully human antibodies addressing life-threatening infections and other diseases. IQ-DAA contains two unique antibodies to neutralize Anthrax lethal toxin and it has been demonstrated to be very efficacious in animal models. It has the potential to become an important addition to the arsenal of medical countermeasures."

The clinical trial involves 32 healthy volunteers and it is being conducted by QPS Netherlands BV. The trial will be a randomized, placebo-controlled, double blind, single dose-escalating study that will focus on the tolerability and safety of IQNLF, a component of IQ-DAA.